Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
Authors
Keywords
-
Journal
Cancer Medicine
Volume 8, Issue 13, Pages 5988-5994
Publisher
Wiley
Online
2019-08-25
DOI
10.1002/cam4.2505
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
- (2019) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study
- (2018) Andrew Brenner et al. NEURO-ONCOLOGY
- Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.
- (2018) Kent C. Shih et al. JOURNAL OF CLINICAL ONCOLOGY
- ACTR-17. EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY
- (2018) Andrew J Brenner et al. NEURO-ONCOLOGY
- Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma
- (2017) Janice K. Laramy et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- New Directions in Anti-Angiogenic Therapy for Glioblastoma
- (2017) Nancy Wang et al. Neurotherapeutics
- Lomustine and Bevacizumab in Progressive Glioblastoma
- (2017) Wolfgang Wick et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Does ponatinib cross the blood-brain barrier?
- (2016) Muhammad B. Abid et al. BRITISH JOURNAL OF HAEMATOLOGY
- Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab
- (2014) William Magnuson et al. JOURNAL OF NEURO-ONCOLOGY
- Prospective, high-throughput molecular profiling of human gliomas
- (2012) Andrew S. Chi et al. JOURNAL OF NEURO-ONCOLOGY
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
- (2012) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
- (2010) Richard M. Zuniga et al. JOURNAL OF NEURO-ONCOLOGY
- Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
- (2009) Eudocia C. Quant et al. NEURO-ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy
- (2008) Jinyan Du et al. NATURE BIOTECHNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started